Equities

Haleon PLC

HLN:LSE

Haleon PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)372.40
  • Today's Change0.00000000000006 / 0.00%
  • Shares traded19.15m
  • 1 Year change13.88%
  • Beta--
Data delayed at least 20 minutes, as of Nov 21 2024 17:02 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Haleon plc is a consumer healthcare company. The Company's product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.

  • Revenue in GBP (TTM)11.24bn
  • Net income in GBP1.21bn
  • Incorporated2021
  • Employees24.00k
  • Location
    Haleon PLCBuilding 5, First Floor, The HeightsWEYBRIDGE KT13 0NYUnited KingdomGBR
  • Phone+44 19 3282 2000
  • Websitehttps://www.haleon.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Biogen Inc7.63bn1.28bn18.06bn7.57k18.06bn7.57k
Alnylam Pharmaceuticals, Inc.1.66bn-263.93m25.49bn2.10k25.49bn2.10k
Otsuka Holdings Co Ltd11.67bn779.13m25.81bn34.39k25.81bn34.39k
UCB SA4.54bn199.69m27.50bn9.08k27.50bn9.08k
Haleon PLC11.24bn1.21bn33.37bn24.00k33.37bn24.00k
Takeda Pharmaceutical Co Ltd23.37bn1.49bn34.20bn49.28k34.20bn49.28k
Jiangsu Hengrui Pharmaceuticals Co Ltd2.85bn597.96m35.33bn19.61k35.33bn19.61k
Sun Pharmaceutical Industries Ltd4.73bn1.04bn40.08bn43.00k40.08bn43.00k
Daiichi Sankyo Co Ltd9.04bn1.29bn45.06bn18.73k45.06bn18.73k
Merck KGaA17.44bn2.24bn49.96bn62.26k49.96bn62.26k
Data as of Nov 21 2024. Currency figures normalised to Haleon PLC's reporting currency: UK Pound GBX

Institutional shareholders

18.33%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 05 Nov 2024249.86m2.76%
Dodge & Coxas of 30 Sep 2024233.28m2.58%
BlackRock Fund Advisorsas of 07 Nov 2024196.44m2.17%
BlackRock Investment Management (UK) Ltd.as of 05 Nov 2024159.50m1.76%
Norges Bank Investment Managementas of 05 Nov 2024151.87m1.68%
MFS International (UK) Ltd.as of 05 Nov 2024151.18m1.67%
Franklin Mutual Advisers LLCas of 05 Nov 2024135.75m1.50%
First Eagle Investment Management LLCas of 05 Nov 2024134.03m1.48%
Harding Loevner LPas of 05 Nov 2024132.71m1.47%
GIC Pte Ltd. (Investment Management)as of 05 Nov 2024114.87m1.27%
More ▼
Data from 30 Jun 2024 - 08 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.